12:00 AM
Nov 05, 2007
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AT2391: Phase I data

In an ongoing, open-label, U.S. Phase I trial, data from 7 evaluable patients showed that AT2391 provided steady basal levels of insulin....

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >